Business
China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved PECONDLE® (picankibart injection), a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody, for the treatment of moderate-to-seve
About this update from Innovent Biologics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"PECONDLE® (picankibart injection) has received approval from China's National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy.","length":238,"tagName":"p"}]},{"val":[{"type":"text","content":"PECONDLE® is the world's first IL-23p19 antibody whose registrational Phase 3 clinical trial met its primary endpoint with over 80% of subjects achieving a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at Week 16.","length":238,"tagName":"p"}]},{"val":[{"type":"text","content":"Among comparable biologics, PECONDLE® offers the longest dosing interval during the maintenance period (once every 12 weeks). It is poised to provide Chinese patients with moderate-to-severe plaque psoriasis comprehensive benefits, including significant skin clearance, improved quality of life, and enhanced dosing convenience.","length":328,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":804,"olType":false},{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved PECONDLE® (picankibart injection), a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy.","length":657,"tagName":"p"},{"type":"text","content":"At present, the number of patients with psoriasis in China exceeds 7 million, among which the number of plaque psoriasis patients is the large, and the disease is characterized by chronicity and recurrence, often accompanied by itching, pain, scaling and changes in appearance, which significantly affect quality of life and mental health. In addition to skin involvement, patients often experience comorbidities such as cardiometabolic risk (hypertension, dyslipidemia, obesity, abnormal glucose and lipid metabolism, etc.) as well as depression and anxiety, a...